Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,778,962

« Back to Dashboard
Patent 8,778,962 protects AFINITOR and AFINITOR DISPERZ and is included in two NDAs. There have been two Paragraph IV challenges on Afinitor.

Protection for AFINITOR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 8,778,962

Title:Treatment of solid tumors with rapamycin derivatives
Abstract: Rapamycin derivatives have interesting effects in the treatment of solid tumours, optionally in combination with a chemotherapeutic agent.
Inventor(s): Lane; Heidi (Basel, CH), O'Reilly; Terence (Basel, CH), Wood; Jeanette Marjorie (Biel-Benken, CH)
Assignee: Novartis Pharmaceuticals Corporation (East Hanover, NJ)
Application Number:13/546,686
Patent Claim Types:
see list of patent claims
Use; Dosage form; Delivery;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 0th percentile
Forward Citations: 1st percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
TABLET;ORAL022334-003Jul 9, 2010RXNo8,778,962*PEDAug 18, 2022Y
TABLET;ORAL022334-001Mar 30, 2009RXNo8,778,962*PEDAug 18, 2022Y
TABLET;ORAL022334-004Mar 30, 2012RXNo8,778,962*PEDAug 18, 2022Y
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,778,962

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0104072.4Feb 19, 2001
United Kingdom0124957.2Oct 17, 2001

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.